Lasa Supergenerics liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

0.08×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.62×	0.62×	1.90×	0.78×	0.92×
0.51×	0.51×	0.47×	0.39×	0.59×
0.3	0.3	0.3	0.6	0.8
−6.3	−6.3	15.4	−11.0	−3.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health

₹ CrorePeersMANGALAM BIOFILCHEM ORTINGLOBE VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹23.4 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	0.08
Current Ratio	0.92	0.78	1.90	0.62	0.62
Quick Ratio	0.59	0.39	0.47	0.51	0.51
Cash, Equiv & ST Investments	0.8	0.6	0.3	0.3	0.3
Working Capital	-3.5	-11.0	15.4	-6.3	-6.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.